Palvella director reports no PVLA share ownership

PALVELLA THERAPEUTICS, INC. director Matthew Pauls has filed an initial Form 3, which is the first statement of his beneficial ownership as an insider.

Rhea-AI Filing Summary

PALVELLA THERAPEUTICS, INC. director Matthew Pauls has filed an initial Form 3, which is the first statement of his beneficial ownership as an insider. This filing reports no purchases, sales, gifts, or other share movements and lists no derivative positions for him in this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Matthew Pauls’ Form 3 for PVLA show?

The Form 3 shows that Matthew Pauls is an insider of Palvella Therapeutics as a director. This specific filing reports no share purchases, sales, gifts, or other movements, and lists no derivative positions for him in the summary data.

Are there any share transactions reported for PVLA director Matthew Pauls?

No, this Form 3 reports zero share transactions for Matthew Pauls. The transaction summary shows no buys, sells, exercises, gifts, tax withholdings, or restructurings, indicating only his insider status is being recorded in this filing.

Does the PVLA Form 3 disclose any derivative positions for Matthew Pauls?

No, the derivative summary in this Form 3 is empty. That means the filing does not list any options, warrants, or other derivative securities held by Matthew Pauls as part of this initial beneficial ownership statement.

What role does Matthew Pauls have at Palvella Therapeutics (PVLA)?

Matthew Pauls is identified as a director of Palvella Therapeutics. The Form 3 confirms his status as an insider director but does not show any corresponding share transactions or derivative holdings in the reported data.

Why is this PVLA Form 3 filing important for investors?

Form 3 filings mark when someone becomes an insider of a public company. This report records director Matthew Pauls’ insider status at Palvella Therapeutics, providing a baseline for any future Form 4 or Form 5 transaction reports involving him.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pauls Matthew

(Last) (First) (Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/29/2026

3. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)